Edwards Lifesciences Corp's stock fell 3.02% and hit a 20-day low amid broader market declines, with the Nasdaq-100 down 1.54% and the S&P 500 down 0.80%.
The U.S. District Court blocked Edwards Lifesciences' acquisition of JenaValve, which the company believed would benefit underserved patients. Despite this setback, Edwards raised its 2026 adjusted EPS guidance to a range of $2.90 to $3.05, exceeding analyst expectations, reflecting confidence in its future performance and ongoing commitment to innovation in heart disease treatments.
The acquisition blockage presents challenges for Edwards' market expansion strategy, but the company remains focused on advancing its SOJOURN transcatheter AR valve and enrolling patients in the JOURNEY pivotal trial, indicating a strong commitment to improving patient care.
Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 96.52 USD with a low forecast of 84.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
24 Analyst Rating
Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 96.52 USD with a low forecast of 84.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 81.860
Low
84.00
Averages
96.52
High
105.00
Current: 81.860
Low
84.00
Averages
96.52
High
105.00
Stifel
Buy
maintain
$105 -> $110
2026-01-20
Reason
Stifel
Price Target
$105 -> $110
AI Analysis
2026-01-20
maintain
Buy
Reason
Stifel raised the firm's price target on Edwards Lifesciences to $110 from $105 and keeps a Buy rating on the shares, reporting that the firm's fifty physician TAVR survey results were "highly encouraging for TAVR growth as a whole and Edwards specifically."
Piper Sandler
Overweight
maintain
$95 -> $98
2026-01-20
Reason
Piper Sandler
Price Target
$95 -> $98
2026-01-20
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Edwards Lifesciences to $98 from $95 and keeps an Overweight rating on the shares. The firm is updating a handful of its models to adjust for preliminary Q4 results and initial full year 2026 guidance announcements from this past week or so.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EW
Unlock Now
Goldman Sachs
David Roman
Buy
maintain
$104 -> $108
2026-01-09
Reason
Goldman Sachs
David Roman
Price Target
$104 -> $108
2026-01-09
maintain
Buy
Reason
Goldman Sachs analyst David Roman raised the firm's price target on Edwards Lifesciences to $108 from $104 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
TD Cowen
Hold
to
Buy
upgrade
$90 -> $97
2026-01-09
Reason
TD Cowen
Price Target
$90 -> $97
2026-01-09
upgrade
Hold
to
Buy
Reason
TD Cowen upgraded Edwards Lifesciences to Buy from Hold with a price target of $97, up from $90. The firm thinks the company has entered a renewed growth cycle, driven by TAVR indication expansion, reinforced Sapien durability from the seven-year PARTNER 3 results, and accelerating momentum with Evoque. TD sees a path to sustained double-digit organic growth for Edwards.
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
